Clement L Ren1, Aliza K Fink2, Kristofer Petren2, Drucy S Borowitz3, Susanna A McColley4, Don B Sanders5, Margaret Rosenfeld6, Bruce C Marshall2. 1. Division of Pediatric Pulmonology, Department of Pediatrics, University of Rochester, Rochester, New York; clement_ren@urmc.rochester.edu. 2. Cystic Fibrosis Foundation, Bethesda, Maryland; 3. Division of Pediatric Pulmonology, Department of Pediatrics, Women and Children's Hospital of Buffalo, Buffalo, New York; 4. Department of Pediatrics, Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois; 5. Division of Pediatric Pulmonology, Cystic Fibrosis, and Sleep Medicine/Department of Pediatrics, University of Wisconsin, Madison, Wisconsin; and. 6. Division of Pulmonary Medicine, Seattle Children's Hospital and Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Abstract
BACKGROUND AND OBJECTIVES: Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS) describes asymptomatic infants with a positive cystic fibrosis (CF) newborn screen (NBS) but inconclusive diagnostic testing for CF. Little is known about the epidemiology and outcomes of CRMS. The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We analyzed data from the US CF Foundation Patient Registry (CFFPR) from 2010 to 2012. We compared demographic, diagnostic, anthropometric, health care utilization, microbiology, and treatment characteristics between infants with CF and infants with CRMS. RESULTS: There were 1983 infants diagnosed via NBS between 2010 and 2012 reported to the CFFPR. By using the CF Foundation guideline definitions, 1540 and 309 infants met the criteria for CF and CRMS, respectively (CF:CRMS ratio = 5.0:1.0). Of note, 40.8% of infants with CRMS were entered into the registry with a clinical diagnosis of CF. Infants with CRMS tended to have normal nutritional indices. However, 11% of infants with CRMS had a positive Pseudomonas aeruginosa respiratory tract culture in the first year of life. CONCLUSIONS: CRMS is a common outcome of CF NBS, and some infants with CRMS may develop features concerning for CF disease. A substantial proportion of infants with CRMS were assigned a clinical diagnosis of CF, which may reflect misclassification or clinical features not collected in the CFFPR.
BACKGROUND AND OBJECTIVES:Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS) describes asymptomatic infants with a positive cystic fibrosis (CF) newborn screen (NBS) but inconclusive diagnostic testing for CF. Little is known about the epidemiology and outcomes of CRMS. The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS. METHODS: We analyzed data from the US CF Foundation Patient Registry (CFFPR) from 2010 to 2012. We compared demographic, diagnostic, anthropometric, health care utilization, microbiology, and treatment characteristics between infants with CF and infants with CRMS. RESULTS: There were 1983 infants diagnosed via NBS between 2010 and 2012 reported to the CFFPR. By using the CF Foundation guideline definitions, 1540 and 309 infants met the criteria for CF and CRMS, respectively (CF:CRMS ratio = 5.0:1.0). Of note, 40.8% of infants with CRMS were entered into the registry with a clinical diagnosis of CF. Infants with CRMS tended to have normal nutritional indices. However, 11% of infants with CRMS had a positive Pseudomonas aeruginosa respiratory tract culture in the first year of life. CONCLUSIONS: CRMS is a common outcome of CF NBS, and some infants with CRMS may develop features concerning for CF disease. A substantial proportion of infants with CRMS were assigned a clinical diagnosis of CF, which may reflect misclassification or clinical features not collected in the CFFPR.
Authors: Debra Boyer; Mary Nevin; Carey C Thomson; Don B Sanders; Stamatia Alexiou; Samuel B Goldfarb; Jennifer L Nicholas; Paul G Thacker; Andrea M Coverstone; Albert Faro; George Cheng; Adnan Majid; Paul E Moore Journal: Ann Am Thorac Soc Date: 2015-11
Authors: Sonya L Heltshe; Jonathan Cogen; Kathleen J Ramos; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2017-04-15 Impact factor: 21.405
Authors: H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell Journal: Clin Genet Date: 2016-01-20 Impact factor: 4.438
Authors: Jeffrey S Wagener; Stefanie J Millar; Nicole Mayer-Hamblett; Gregory S Sawicki; Edward F McKone; Christopher H Goss; Michael W Konstan; Wayne J Morgan; David J Pasta; Richard B Moss Journal: J Cyst Fibros Date: 2017-10-31 Impact factor: 5.482
Authors: Martina I Lefterova; Peidong Shen; Justin I Odegaard; Eula Fung; Tsoyu Chiang; Gang Peng; Ronald W Davis; Wenyi Wang; Martin Kharrazi; Iris Schrijver; Curt Scharfe Journal: J Mol Diagn Date: 2016-02-01 Impact factor: 5.568
Authors: Christopher H Goss; Jenna Sykes; Sanja Stanojevic; Bruce Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Bradley S Quon; Anne L Stephenson Journal: Am J Respir Crit Care Med Date: 2018-03-15 Impact factor: 30.528